All Articles

Octave Specialty Group's core insurance unit saw 77% revenue growth, fueled by strategic buys and a new AI underwriting platform that signals a tech-led future.

After two years of losses, Silvaco is back in the black. A deep dive into the AI strategy and key partnerships with NVIDIA, Micron, and Dassault driving its comeback.

While Q2 results show a net loss, Bridger Aerospace secures record contracts and expands its tech, signaling a strategic shift for a new era of wildfire.

iRhythm's stellar Q2 results are just the start. A major acquisition and a new AI algorithm are set to reshape the cardiac monitoring landscape.

Kodiak AI posts strong Q2 growth and unveils its Gen7 platform, accelerating its push for driverless long-haul. But can revenue outpace a steep cash burn?

Arlo Technologies smashed expectations with record revenue, fueled by a masterful pivot to recurring services that now form the core of its business.

Rigetti Computing posts a $52.6M quarterly loss but secures major partnerships and potential government funding, betting big on its long-term quantum strategy.

electroCore posts strong Q2 growth and raises guidance, driven by a federal market focus. But as the company maps a path to profitability, a closer look reveals a race between strategic execution and a dwindling cash runway.

Zentalis Pharmaceuticals is pursuing a dual strategy for its ovarian cancer drug, azenosertib, aiming for fast market entry while securing long-term validation.

Artiva Biotherapeutics secures FDA fast-track status for its novel NK cell therapy, AlloNK. This could revolutionize autoimmune care for millions.

NATR's Q2 results show a firm investing heavily in its digital future, with soaring e-commerce sales and subscription growth offsetting currency and China woes.

Beyond the mixed GAAP results, ICU Medical’s strong non-GAAP growth and raised guidance reveal a company thriving after a strategic pivot.

With 13% revenue growth and a massive buyback, CarGurus' Q2 results show its AI-first strategy is reshaping the auto market and rewarding investors.

With its lead obesity drug in late-stage trials and a Novo Nordisk veteran newly hired, Structure Therapeutics is making a calculated play for the oral GLP-1 crown.

Apyx Medical's Q2 results show a 28% surge in its aesthetics unit, driven by the new AYON system. Is this strategic pivot away from OEM the key to its future?

The software supply chain firm's Q2 results beat estimates, with cloud revenue soaring 53% as its security platform becomes essential for the AI era.

The nation's only public parking firm faces an insider offer, placing a special committee at the center of a high-stakes test for shareholder value.

With late-stage trials underway and a cash runway into 2030, Trevi Therapeutics is accelerating its mission. But what does this mean for millions of unseen sufferers?

A new press release touts 'simplicity' as the future of digital entertainment. But for online gaming platform Mr Win77, are the real complexities hidden?

With nearly $1B in cash and a shrinking net loss, Janux is pushing its advanced prostate cancer drugs while its novel autoimmune therapy nears a key data reveal.